[HTML][HTML] Recurrent idiopathic membranous nephropathy: early diagnosis by protocol biopsies and treatment with anti-CD20 monoclonal antibodies
ZM El-Zoghby, JP Grande, MG Fraile, SM Norby… - American Journal of …, 2009 - Elsevier
Membranous nephropathy (MN) recurs posttransplant in 42% of patients. We compared MN
recurrence rates in a historical cohort transplanted between 1990 and 1999 and in a current
cohort diagnosed by protocol biopsies, we analyzed the progression of the disease and we
assessed the effects of anti-CD20 antibodies (Rituximab) on recurrent MN. The incidence of
recurrent MN was similar in the historical (53%) and the current cohorts (41%), although in
the later the diagnosis was made earlier (median, 4 [2–21] months vs. 83 [6–149], p= 0.002) …
recurrence rates in a historical cohort transplanted between 1990 and 1999 and in a current
cohort diagnosed by protocol biopsies, we analyzed the progression of the disease and we
assessed the effects of anti-CD20 antibodies (Rituximab) on recurrent MN. The incidence of
recurrent MN was similar in the historical (53%) and the current cohorts (41%), although in
the later the diagnosis was made earlier (median, 4 [2–21] months vs. 83 [6–149], p= 0.002) …
